Skip to main content
رجوع
ALNY logo

Alnylam Pharmaceuticals, Inc.

جودة البيانات: 100%
ALNY
NASDAQ Healthcare Biotechnology
KWD 328.70
▲ KWD 20.65 (6.70%)
القيمة السوقية: 43.59B
نطاق اليوم
KWD 311.71 KWD 329.48
نطاق 52 أسبوعًا
KWD 205.87 KWD 495.55
حجم التداول
1,098,817
متوسط 50 يوم / 200 يوم
KWD 337.90 / KWD 392.53
الإغلاق السابق
KWD 308.05

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 138.9 0.3
P/B 55.2 3.0
ROE % 73.3 3.7
Net Margin % 8.5 3.8
Rev Growth 5Y % 44.8 10.0
D/E 1.6 0.2

السعر المستهدف للمحللين

Hold
KWD 460.50 +40.1%
Low: KWD 351.00 High: KWD 549.00
مكرر الربحية المستقبلي
48.33
ربحية السهم المستقبلية
KWD 6.80
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
5.56B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 19.29
KWD 16.99 – KWD 23.76
 11.36B 14
FY2029 KWD 16.25
KWD 14.31 – KWD 20.01
 9.98B 14
FY2028 KWD 13.74
KWD 9.81 – KWD 20.45
 8.76B 16

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-12 KWD 1.16 KWD 1.25 +7.8%
2025-10-30 KWD 0.56 KWD 2.90 +416.9%
2025-07-31 -KWD 0.54 KWD 0.32 +158.9%
2025-05-01 -KWD 0.89 -KWD 0.01 +98.9%
2025-02-13 -KWD 0.62 KWD 0.06 +109.7%
2024-10-31 -KWD 0.92 -KWD 0.50 +45.5%
2024-08-01 -KWD 1.07 KWD 0.56 +152.3%
2024-05-02 -KWD 1.12 -KWD 0.16 +85.7%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 44.82% annually over 5 years — strong growth
ROE of 73.28% indicates high profitability
Generating 465.38M in free cash flow
P/E of 138.94 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 20.37%
Cash machine — converts 148.33% of earnings into free cash flow

النمو

Revenue Growth (5Y)
44.82%
Revenue (1Y)65.19%
Earnings (1Y)N/A
FCF Growth (3Y)233.09%

الجودة

Return on Equity
73.28%
ROIC18.19%
Net Margin8.45%
Op. Margin13.51%

الأمان

Debt / Equity
1.62
Current Ratio2.76
Interest Coverage1.99

التقييم

P/E Ratio
138.94
Forward P/E48.33
P/B Ratio55.24
EV/EBITDA86.16
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 65.19% Revenue Growth (3Y) 42.53%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 44.82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.71B Net Income (TTM) 313.75M
ROE 73.28% ROA 6.32%
Gross Margin 81.77% Operating Margin 13.51%
Net Margin 8.45% Free Cash Flow (TTM) 465.38M
ROIC 18.19% FCF Growth (3Y) 233.09%
Safety
Debt / Equity 1.62 Current Ratio 2.76
Interest Coverage 1.99
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 138.94 Forward P/E 48.33
P/B Ratio 55.24 P/S Ratio 11.74
PEG Ratio -0.79 Forward PEG N/A
EV/EBITDA 86.16 Fwd EV/EBITDA N/A
Forward P/S 7.84 Fwd Earnings Yield 2.07%
FCF Yield 1.07%
Market Cap 43.59B Enterprise Value 43.21B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.71B 2.25B 1.83B 1.04B 844.29M
Net Income 313.75M -278.16M -440.24M -1.13B -852.82M
EPS (Diluted) 2.33 -2.18 -3.52 -9.30 -7.20
Gross Profit 3.04B 1.92B 1.52B 868.60M 704.14M
Operating Income 501.58M -176.89M -282.18M -785.07M -708.65M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4.97B 4.24B 3.83B 3.55B 3.64B
Total Liabilities 4.18B 4.17B 4.05B 3.70B 3.06B
Shareholders' Equity 789.18M 67.09M -220.64M -158.22M 588.20M
Total Debt 1.28B 2.74B 1.31B 1.32B 997.59M
Cash & Equivalents 1.66B 966.43M 812.69M 866.39M 819.98M
Current Assets 4.05B 3.30B 2.98B 2.69B 2.81B
Current Liabilities 1.47B 1.19B 967.79M 767.92M 695.71M